SLC5A2 and type 2 diabetes mellitus: 289 Zelniker Zelniker T.A. T.A. Wiviott Wiviott S.D. S.D. Raz Raz I. I. Im Im K. K. Goodrich Goodrich E.L. E.L. Furtado Furtado R.H.M. R.H.M. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Circulation.